News
-
Malvern Instruments has announced that it will team up with Proveris Scientific Corporation on a nasal spray characterization system called Solo for Spraytec, which combines Proveris’s automated actuator and software for precise control of device… Read more . . .
-
Inhaled drug developer Vectura has announced better than expected preliminary results for the year ending March 31, 2013, with the company’s loss before tax 21% lower than in 2011/12. The company also announced that Paul… Read more . . .
-
According to Sunovion Pharmaceuticals, data from a year-long clinical trial comparing the safety of Brovana arformoterol tartrate inhalation solution versus placebo in patients with moderate-to-severe COPD show no increased risk of exacerbations or death due… Read more . . .
-
Pearl Therapeutics has announced the initiation of a Phase 3 program called PINNACLE for its PT003 glycopyrrolate/formoterol fumarate metered dose inhaler for patients with moderate-to-severe COPD. The program will include two studies involving more than… Read more . . .
-
According to Aegis Therapeutics, the company has been granted US Patent No. 8,440,631 for fast-acting formulations of triptans for the treatment of migraines. The patent is the second for Aegis’s triptan nasal sprays using its… Read more . . .
-
The European Patent Office will grant Insmed Incorporated EU Patent No. 1909759 for Arikace liposomal amikacin for inhalation, according to Insmed. The composition of matter patent, titled “Sustained release of anti-infective aminoglycosides,” covers formulations of… Read more . . .
-
Elan Corporation has announced that it will pay Theravance $1 billion for a 21% participation interest in future royalty payments from sales of Breo (Relvar) Ellipta, Anoro Ellipta, MABA ‘081 bifunctional muscarinic antagonist-beta2 agonist monotherapy,… Read more . . .
-
Vectura has announced that it has partnered with Chinese pharmaceutical company Tianjin KingYork Group and Hong Kong private equity investor Zendex Bio Strategy to create Tianjin Kinnovata Pharmaceutical Company Limited (“Kinnovata”). The new company will… Read more . . .
-
The FDA has approved GSK and Theravance’s Breo Ellipta fluticasone furoate/vilanterol inhalation powder for the treatment of COPD). The FDA’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted to recommend approval of Breo Ellipta in April 2013.… Read more . . .
-
A UK innovation agency, the Technology Strategy Board, has awarded Team Consulting a grant to fund an 8-month feasibility test of its Occoris inhaler “engine” technology, the company said. According to Team, the Occoris engine,… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.